Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|172|5|1395-1406

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.172, Iss.5, 2015-05, pp. : 1395-1406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 949-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 9, 2015-09 ,pp. : 1742-1749

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, efficacy, and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e163-e163

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 509-519

John Wiley & Sons Inc

Access to resources Recommend Favorite